{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:53Z","timestamp":1740149813288,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12328-022-01650-4","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T13:04:08Z","timestamp":1657285448000},"page":"784-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improvement of vanishing bile duct syndrome with hyperlipidemia"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-8326","authenticated-orcid":false,"given":"Ryo","family":"Yamauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5:58.","journal-title":"Nat Rev Dis Primers"},{"key":"1650_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cld.2016.08.007","volume":"21","author":"H Saithanyamurthi","year":"2017","unstructured":"Saithanyamurthi H, Faust AJ. Drug-induced liver disease: clinical course. Clin Liver Dis. 2017;21:21\u201334.","journal-title":"Clin Liver Dis"},{"key":"1650_CR3","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1007\/s10620-017-4812-7","volume":"62","author":"J Ahmad","year":"2017","unstructured":"Ahmad J, Odin JA, Hayashi PH, et al. Identifcation and characterization of fenofbrate-induced liver injury. Dig Dis Sci. 2017;62:3596\u2013604.","journal-title":"Dig Dis Sci"},{"key":"1650_CR4","first-page":"245","volume":"67","author":"CY Ho","year":"2004","unstructured":"Ho CY, Kuo TH, Chen TS, et al. Fenofbrate-induced acute cholestatic hepatitis. J Chin Med Assoc. 2004;67:245\u20137.","journal-title":"J Chin Med Assoc"},{"key":"1650_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0248-8663(89)80119-5","volume":"10","author":"J Rigal","year":"1989","unstructured":"Rigal J, Furet Y, Autret E, et al. Severe mixed hepatitis caused by fenofibrate? A review of the literature apropos of a case. Rev Med Interne. 1989;10:65\u20137.","journal-title":"Rev Med Interne"},{"key":"1650_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1472-8206.2009.00791.x","volume":"24","author":"S Kastalli","year":"2010","unstructured":"Kastalli S, El A\u00efdli S, Za\u00efem A, et al. Fatal liver injury associated with clopidogrel. Fundam Clin Pharmacol. 2010;24:433\u20135.","journal-title":"Fundam Clin Pharmacol"},{"key":"1650_CR7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jgh.14503","volume":"34","author":"J Tejedor-Tejada","year":"2019","unstructured":"Tejedor-Tejada J, Garc\u00eda-Pajares F, Madrigal RB. Hepatobiliary and pancreatic: sertraline-induced vanishing bile duct syndrome treated with plasmapheresis. J Gastroenterol Hepatol. 2019;34:488.","journal-title":"J Gastroenterol Hepatol"},{"key":"1650_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2957\/kanzo.46.85","volume":"46","author":"H Takikawa","year":"2005","unstructured":"Takikawa H, Onji M, Takamori Y, et al. Proposal of diagnostic criteria for drug-induced hepatic injury revised by the DDW-J2004 Workshop. Kanzo. 2005;46:85\u201390 ((in Japanese)).","journal-title":"Kanzo"},{"key":"1650_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267\u201377.","journal-title":"Hepatology"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0168-8278(88)80482-3","volume":"7","author":"J Ludwig","year":"1988","unstructured":"Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol. 1988;7:193\u20139.","journal-title":"J Hepatol"},{"key":"1650_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","volume":"1864","author":"M Visentin","year":"2018","unstructured":"Visentin M, Lenggenhager D, Gai Z, et al. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1498\u2013506.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1650_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1055\/s-2007-1007354","volume":"13","author":"GM Woolf","year":"1993","unstructured":"Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis. 1993;13:261\u201375.","journal-title":"Semin Liver Dis"},{"key":"1650_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-8278(97)82330-6","volume":"26","author":"VJ Desmet","year":"1997","unstructured":"Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 1997;26:31\u20135.","journal-title":"J Hepatol"},{"key":"1650_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"J-C Fruchart","year":"2017","unstructured":"Fruchart J-C. Pemafibrate (K-877), a novel selective peroxisome proliferator activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16:124.","journal-title":"Cardiovasc Diabetol"},{"key":"1650_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5551\/jat.48918","volume":"26","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPAR \u03b3 modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389\u2013402.","journal-title":"J Atheroscler Thromb"},{"key":"1650_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","volume":"34","author":"DB Miller","year":"1998","unstructured":"Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155\u201362.","journal-title":"Clin Pharmacokinet"},{"key":"1650_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/qjmed\/hcn089","volume":"101","author":"R Bhindi","year":"2008","unstructured":"Bhindi R, Ormerod O, Newton J, et al. Interaction between stains and clopidogrel: is there anything clinically relevant? QMJ. 2008;101:915\u201325.","journal-title":"QMJ"},{"key":"1650_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.4254\/wjh.v8.i22.924","volume":"8","author":"K Nemes","year":"2016","unstructured":"Nemes K, Aberg F, Gylling H, et al. Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications. World J Hepatol. 2016;8:924\u201332.","journal-title":"World J Hepatol"},{"key":"1650_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12876-018-0869-9","volume":"18","author":"W Xie","year":"2018","unstructured":"Xie W, Wang Q, Gao Y, et al. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report. BMC Gastroenterol. 2018;18:142.","journal-title":"BMC Gastroenterol"},{"key":"1650_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajg.2016.08.006","volume":"17","author":"A Basturk","year":"2016","unstructured":"Basturk A, Artan R, Yilmaz A, et al. Acute vanishing bile duct syndrome after the use of ibuprofen. Arab J Gastroenterol. 2016;17:137\u20139.","journal-title":"Arab J Gastroenterol"},{"key":"1650_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5223\/pghn.2013.16.4.273","volume":"16","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Jwa HJ, Kim KS, et al. Ursodeoxycholic acid therapy in a child with trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Pediatr Gastroenterol Hepatol Nutr. 2013;16:273\u20138.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3349\/ymj.2014.55.3.834","volume":"55","author":"HY Kim","year":"2014","unstructured":"Kim HY, Yang HK, Kim SH, et al. Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant. Yonsei Med J. 2014;55:834\u20137.","journal-title":"Yonsei Med J"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01650-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:49:47Z","timestamp":1700822987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01650-4","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animal performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}